Both ROI-based and voxel-based analyses revealed reduced DMN connectivity in patients with iNPH. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
38/100
There was decreased activity in the left inferior parietal cortex (IPC) and the left posterior cingulate cortex (PCC) within the DMN between PDAR and both HC and PDT subjects, even after controlling for multiple comparisons, but not between PDT and HC. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Patients showed increased connectivity around the medial prefrontal cortex in the anterior sub-network, but decreased connectivity around the posterior cingulate cortex in the posterior sub-network. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
There were no group differences in cortical thickness but functional coactivation within components of the DMN was significantly lower in both PDVH and PDnonVH groups compared to HC. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Altered functional characteristics have been reported in amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD); nonetheless, comprehensive analyses of the resting-state networks (RSNs) are rare. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A decreased dorsal salience network (DSN) connectivity, mainly involving the anterior cingulum, was observed in bvFTD versus controls and pAD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
White matter lesions (WMLs) are notable for their high prevalence and have been demonstrated to be a potential neuroimaging biomarker of early diagnosis of Alzheimer's disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
38/100
Different aspects of the self have been reported to be affected in many neurological or psychiatric diseases such as Alzheimer's disease (AD), including mainly higher-level cognitive self-unawareness. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Studies involving linear measurements of ventricular size and a volumetric measurement of the cerebrospinal fluid (CSF) space were performed on elderly subjects with mild dementia of the Alzheimer type and on age-matched controls. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
38/100
Studying eye movements can provide insight into how the normal brain works, how diseases affect eye movements, and how eye movement abnormalities can be used to study diseases and/or their treatments. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Central nervous system (CNS) pathologies have ocular manifestations due to direct and/or retrograde degeneration of the visual pathways, most often related to a direct injury to the optic nerve, retinal ganglion cells and/or its surrounding cells. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a devastating neurodegenerative disease characterised clinically by a progressive decline in executive functions, memory and cognition. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The noninvasive techniques of static and dynamic light scattering are emerging as valuable diagnostic tools for the early detection of ocular and systemic diseases. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a progressive neurodegenerative disorder resulting in dementia and eventual death. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Although cerebral small vessel disease has been linked to stroke and dementia, due to limitations of current neuroimaging technology, direct in vivo visualization of changes in the cerebral small vessels (e.g., cerebral arteriolar narrowing, tortuous microvessels, blood-brain barrier damage, capillary microaneurysms) is difficult to achieve. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Although cerebral small vessel disease has been implicated in the development of Alzheimer's disease (AD), the cerebral microcirculation is difficult to visualize directly in vivo. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Redox degenerative reactions of the biological system inevitably produce reactive oxygen species (ROS) and their derivatives. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
38/100
RODBELLFREDRICKSON MDS: The nature of the proteins associated with dog and human chylomicrons. 1 key finding →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source
The proposed Deep-CNN and attention model focuses the model capacity on diagnostically relevant regions. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Three robustly differentiated AD subtypes (S1, S2, and S3) were identified, with 93% validation accuracy and Adjusted Mutual Information scores >0.89, each exhibiting distinct tau patterns. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Three robustly differentiated AD subtypes (S1, S2, and S3) were identified, with 93% validation accuracy and Adjusted Mutual Information scores >0.89, each exhibiting distinct tau patterns. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
PREDICTOM MRI protocol contains eight different datatypes. 5 key findings →
Participants: 615 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
PREDICTOM MRI protocol contains eight different datatypes. 5 key findings →
Participants: 615 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study compared FDG-PET and clinical measurements in elderly subjects with memory disturbance to examine relationships between glucose metabolism and cognitive or functional scores. 3 key findings →
Full summary, score breakdown and related studies → Original source
The olfactory bulb (OB), with its comparatively simple and well-delineated connectivity, presents an interesting system for examining cell-specific pathology in neurologic degenerative disorders such as Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →